Valion Bio Receives Unsolicited Acquisition Interest in Velocity Bioworks; Weighs Strategic Options
Key Highlights
- ➤Valion Bio (VBIO) received unsolicited acquisition inquiries for wholly owned CDMO Velocity Bioworks
- ➤Valion entered preliminary discussions while weighing a possible sale and other strategic options
- ➤Valion retained an investment bank to advise its Board on a potential Velocity transaction
- ➤Any sale could provide capital for Entolimod development and other corporate priorities
- ➤Valion has not committed to a sale; discussions may not produce a definitive agreement
Expert Statements
Dean Zikria, Interim Chief Executive Officer of Valion Bio
“Our strategic review is focused on determining how best to maximize the potential of each asset”
Dean Zikria, Interim Chief Executive Officer of Valion Bio
“The unsolicited interest in Velocity provides an opportunity to evaluate a range of strategic options, including a possible sale. Our priority remains identifying the path that best supports our development objectives and delivers long-term value to shareholders.”
SAN ANTONIO, TX / ACCESS Newswire / October 26, 2026 / Valion Bio, Inc. (NASDAQ:VBIO) ("Valion" or the "Company"), a clinical-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation, today announced that it has received unsolicited acquisition inquiries from independent third parties concerning its wholly owned contract development and manufacturing organization ("CDMO"), Velocity Bioworks ("Velocity"). The Company has entered into preliminary discussions with these interested parties while continuing to evaluate a range of strategic options for Velocity.
These discussions are consistent with the strategic priorities outlined in Valion's October 21, 2026 announcement, including advancing its lead biologic drug candidate, Entolimod, and other pipeline assets, building Velocity's commercial business, and evaluating strategic opportunities for the CDMO subsidiary.
Get started
Create a free account to read the full story.